MAPT and Alzheimer disease: Recently, it has been shown that plasma levels of hyperphosphorylated tau (including both P‐tau181 (Janelidze et al,2020; Karikari et al,2020) and P‐tau217 (Palmqvist et al,2020)) are markedly elevated in patients with AD.